AsianScientist (Oct. 24, 2018) – Chinese pharmaceutical and biomedical technology company WuXi AppTec has launched a DNA-encoded library (DEL) construction and screening platform that could expedite the drug discovery process. The library will also grant researchers easy access to more chemical entities in shorter time frames and at lower cost.
WuXi’s DEL technology uses unique DNA sequences to tag each chemical entity within a library, which allows its easy identification in downstream experiments. The platform was built by a team of interdisciplinary scientists, combining the fields of chemistry, biology, bioinformatics and computational chemistry.
The platform now features 80 billion unique molecules which are structurally diverse and chemically exclusive. WuXi AppTec intends to add 10-20 billion more compounds to the collection. Through evolutionary screening, the unique drug-like libraries expand the accessible number of drug candidates, which could lead to better and faster development of new medicines.
“The WuXi DEL platform is a powerful new capability to enable our customers to explore molecular diversity and generate novel hits for their targets,” said Dr. Steve Yang, executive vice president and chief business officer at WuXi. “The new DEL platform will become a key component of our integrated drug discovery technology solution and lower the barrier for innovation.”
———
Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
